Transsexual breast development

Duration: 12min 16sec Views: 247 Submitted: 13.02.2020
Category: Indian
Reuters Health - Transgender women who take sex hormones to feminize their bodies may not experience as much breast development as they expect, a new European study suggests. For this type of transition, hormone therapy consists of both anti-androgens to block the activity of male sex hormones and curb male characteristics as well as estrogens to encourage breast development and feminization. Only 21 of the trans women attained a bra size of an A cup or larger after one year of hormone therapy, the study found. To assess breast growth, researchers measured the circumference of the chest underneath the breasts and at the largest part of the breasts. The difference between these two measurements can be used to determine breast growth and bra sizes. After one year on hormones, the average difference increased to 7.

Transgender women may get small breasts with hormones

Transgender women may get small breasts with hormones - Reuters

This review will inform radiologists about the evidence base regarding radiographic imaging for transgender individuals and considerations for providing culturally sensitive care for this population. Transgender individuals are increasingly referred for both screening and diagnostic breast imaging. It is important that the clinic environment is welcoming, the medical staff utilize accepted terminology and patients are able to designate their gender and personal history to ensure appropriate care. Hormone and surgical treatments used for transition by many transgender women and men may change the approach to imaging. The risk for breast cancer in transgender individuals is still being defined.

Endocrine Abstracts

Summary: — Trans women on hormone therapy experience the development of breast tissue that is anatomically and histologically identical to cis women. Final breast size is typically reached within two years, although weight gain can also affect breast size. Other antiandrogens such as GnRH analogues, cyproterone acetate, and 5-alpha reductase inhibitors, are not associated with this outcome. Anatomy Timeframe Progestins. In MtF patients, the following changes are expected to occur: increased breast hemicircumference up to 12 cm , enlarged nipple and areole, decreased libido and erections, decreased testicular size.
Searchable abstracts of presentations at key conferences in endocrinology. Background: In male to female transgender patients breast development is a key part in the process of feminization using cross sex hormone therapy. But how much growth, in centimeters or cup-sizes, we can expect is not clear.